- The FDA's delayed approval decision puts Novavax at risk of losing a $175 million deal with Sanofi.
- Novavax shares have plunged over 20% amid the uncertainty.
- Analysts' forecasts suggest a significant upside, yet GuruFocus estimates indicate potential downside.
The FDA's missed deadline for approving Novavax's (NVAX, Financial) COVID-19 vaccine has stirred apprehension within the biotech industry. This delay not only imperils the company’s potential $175 million agreement with Sanofi, which hinges on the vaccine's approval but also leaves the vaccine under a mere emergency use authorization. Following this development, Novavax shares have plummeted over 20% in the last week.
Wall Street Analysts' Perspectives
Presently, six analysts have provided their one-year price targets for Novavax Inc (NVAX, Financial), with an average target price set at $17.67. This reflects a high estimate of $25.00 and a low of $9.00. Based on these numbers, there's an anticipated upside of 195.18% from the current trading price of $5.99. For more in-depth analysis, visit the Novavax Inc (NVAX) Forecast page.
Moreover, a consensus from seven brokerage firms assigns Novavax Inc an average recommendation rating of 2.3, which translates to an "Outperform" status. The rating scale ranges from 1 (Strong Buy) to 5 (Sell).
GuruFocus's GF Value Estimation
According to GuruFocus estimates, Novavax Inc's (NVAX, Financial) GF Value in one year is projected at $4.96. This suggests a potential downside of 17.13% from the current price of $5.985. The GF Value is GuruFocus' calculated fair value for the stock, determined by historical trading multiples, past growth, and future business performance estimates. More detailed insights are available on the Novavax Inc (NVAX) Summary page.
